Efficacy and safety of tofacitinib in young patients aged 2 to less than 18 years with polyarticular course Juvenile Idiopathic Arthritis (JIA)

Efficacy, Safety, and Tolerability of Tofacitinib for Treatment of Polyarticular Course Juvenile Idiopathic Arthritis (JIA) in Children and Adolescent Subjects

Category & Conditions:
Immune System Diseases and Conditions
Medicine:
XELJANZ®(TOFACITINIB)
ClinicalTrials.gov Identifier (NCT):
Protocol ID:
A3921104
Open Plain Language Summary Result:Click here